IL-12-mediated increases in protection elicited by pneumococcal and meningococcal conjugate vaccines

Academic Article


  • Interleukin-12 (IL-12) may be a beneficial adjuvant for augmenting vaccine efficacy against encapsulated bacteria such as Streptococcus pneumoniae and Neisseria meningitidis since it can stimulate production of interferon-γ (IFN-γ) and secretion of antibody isotypes that are efficient at mediating complement fixation and opsonophagocytosis. In this study, we demonstrate the ability of IL-12 to enhance murine antibody responses, particularly IgG2a levels, to both pneumococcal and meningococcal conjugate vaccines. Transfer of immune serum from mice immunized with the meningococcal conjugate vaccine and IL-12 resulted in increased survival times, whereas transfer of serum from mice immunized with the pneumococcal conjugate and IL-12 resulted in protection from death upon bacterial challenge. Although treatment with vaccine and IL-12 increased levels of IFN-γ mRNA, IL-12-mediated enhancement of antibody responses still occurred in IFN-γ-/- mice. The results demonstrate the effectiveness of IL-12 as an adjuvant for polysaccharide conjugate vaccines, especially the pneumococcal conjugate vaccine. © 2001 Elsevier Science Ltd.
  • Authors

    Published In

  • Vaccine  Journal
  • Digital Object Identifier (doi)

    Pubmed Id

  • 9253409
  • Author List

  • Buchanan RM; Briles DE; Arulanandam BP; Westerink MAJ; Raeder RH; Metzger DW
  • Start Page

  • 2020
  • End Page

  • 2028
  • Volume

  • 19
  • Issue

  • 15-16